ALLO at a glance
Allogene Therapeutics, Inc. (ALLO, SEC CIK 1737287) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 2, 2026 and Form 4 insider filings as recently as August 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $190.9 million. Diluted EPS was -$0.87.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Allogene Therapeutics, Inc. (ALLO) shares worth $339.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Douglas Earl Martin on August 21, 2026 of 29,697 shares at $2.12 per share.
- In the last 90 days, ALLO insiders reported 0 open-market purchases ($0) and 1 open-market sale ($63K) on Form 4, a net sale of $63K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$63K
- 13F holders
- 28 funds
- $339.2M · +1 vs prior quarter
- Latest 8-K
- Sep 2, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Net loss $42.7M for Q2 2026; accumulated deficit $2.1B as of June 30, 2026
- ALLO-316 best reported response: 25.0% ORR overall, 31.3% in CD70-high patients
- Cash and investments $423.6M; April 2026 public offering extended runway into Q1 2029
- Continued net losses expected; R&D and G&A expenses expected to increase
Risk Factors
- Newly triggered risk: ALPHA3’s interim futility analysis covered only 24 randomized patients, limiting predictability of primary-endpoint success
- Clinical development risk: FCA-arm termination in ALPHA3 required protocol amendment, adding costs and potentially delaying timelines
- Regulatory risk: ALPHA3 approval may require pairing cema-cel with Foresight Diagnostics’ Clarity MRD companion diagnostic
- Operational risk: Expanding ALPHA3 internationally increases logistical and timing risks for MRD sample testing
- Financial risk: Cash and investments totaled $423.6 million at June 30, 2026, against a $2.1 billion accumulated deficit
AI summary of the ALLO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Geoffrey Parker retiring from Allogene in all capacities effective November 6, 2026
- Principal financial officer transition creates near-term succession and execution risk
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and corporate update announced for quarter ended June 30, 2026
- Financial details and operating developments contained in Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected Deborah Messemer, Vicki Sato and Owen Witte as Class II directors through the 2029 annual meeting
- Executive compensation approved with 213,098,167 votes, supporting current pay practices
Item 8.01: Other Events
- $135.0 million at-the-market equity offering capacity under the existing Sales Agreement
- TD Securities (U.S.A.) LLC serving as sales agent
AI summaries of ALLO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALLO
Don't miss the next ALLO filing
- Alerts as it files. A push when ALLO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALLO, by share count.
- Ask anything. An AI agent that reads every ALLO filing and answers with sources.
ALLO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Douglas Earl Martin | Sell | Aug 21, 2026 | 29,697 | $2.12 |
| Roberts Zachary | A | Jul 1, 2026 | 476,190 | - |
| Roberts Zachary | A | Jul 1, 2026 | 134,530 | - |
| Mayo Stephen | A | Jun 18, 2026 | 144,400 | - |
| Barrett Elizabeth A. | A | Jun 18, 2026 | 95,400 | - |
| Humer Franz B | A | Jun 18, 2026 | 95,400 | - |
| MESSEMER DEBORAH M. | A | Jun 18, 2026 | 95,400 | - |
| Kazam Joshua A | M | Jun 18, 2026 | 47,700 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $95K | $22K | $0 |
| Operating Income | -$327.7M | -$273.2M | -$209.3M |
| Net Income | -$1.6B | -$257.6M | -$190.9M |
| Op. Margin | -344986.3% | -1241813.6% | - |
| Net Margin | -1644421.1% | -1170863.6% | - |
| Balance Sheet | |||
| Total Assets | - | $548.7M | $415.9M |
| Equity | - | $422.2M | $292.5M |
| ROE | - | -61.0% | -65.3% |
| Per Share | |||
| EPS | - | $-1.32 | $-0.87 |
| Cash Flow | |||
| Operating CF | - | -$200.3M | -$149.2M |
| CapEx | $1.5M | $694K | $386K |
Source: XBRL data in Allogene Therapeutics, Inc. (ALLO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ALLO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $339.2M |
| Q1 2026 | 27 | $239.4M |
| Q4 2025 | 23 | $120.2M |
| Q3 2025 | 24 | $114.2M |
| Q2 2025 | 27 | $97.1M |
| Q1 2025 | 23 | $110.0M |
| Q4 2024 | 17 | $163.1M |
| Q3 2024 | 16 | $58.3M |
- BlackRock+11.06M (+58%)
- FMR LLC (Fidelity)+10.42M (+655%)
- State Street Corp+10.37M (+120%)
- Vanguard Capital Management LLC+5.25M (+76%)
- Morgan Stanley+3.51M (+352%)
- T. Rowe Price Group−741.6K (-14%)
- AQR Capital Management−478.5K (-19%)
- U.S. Bancorp−86 (-15%)
- Raymond James Financial+679.0K
- M&T Bank+18.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALLO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 2, 2026 | - | Analysis | - |
| 4 | Aug 25, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 8-K | May 28, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| SC 13G | Apr 23, 2026 | - | - | |
| 4 | Apr 23, 2026 | - | - | - |
| 8-K | Apr 15, 2026 | - | Analysis | - |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Mar 18, 2026 | - | - | - |
| 4 | Mar 18, 2026 | - | - | - |
| 10-K | Mar 12, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
ALLO SEC filings: frequently asked questions
Are ALLO insiders buying or selling?
In the last 90 days, Allogene Therapeutics, Inc. (ALLO) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $62,958 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALLO stock?
As of June 30, 2026, the largest Allogene Therapeutics, Inc. (ALLO) holders among the 13F filers tracked by SignalX were BlackRock ($62.7 million), Pfizer Inc ($46.9 million), State Street Corp ($39.6 million), Vanguard Capital Management LLC ($25.3 million), FMR LLC (Fidelity) ($25.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALLO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $190.9 million. Diluted EPS was -$0.87. The figures come from the XBRL data in the 10-K.
What did ALLO report in its latest 8-K?
Allogene Therapeutics, Inc. (ALLO) filed an 8-K on September 2, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). CFO Geoffrey Parker retiring from Allogene in all capacities effective November 6, 2026.
What are the latest ALLO SEC filings?
Allogene Therapeutics, Inc. (ALLO) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 2, 2026 and a Form 4 insider filing on August 25, 2026.
What is ALLO's SEC CIK number?
Allogene Therapeutics, Inc. (ALLO)'s SEC Central Index Key (CIK) is 1737287. EDGAR lists every ALLO filing under that number.
Ask anything about ALLO
The research agent reads ALLO's filings, financials, insider trades and 13F holders, then answers with sources.